NCT00512525

CompletedPhase 1

Ghrelin Decreases Insulin Sensitivity

University of Aarhus Source

Compare

Other study identifiers

Sponsor study identifier

ETV2007

Study Type

interventional

Actual enrollment (reported)

8

Locations

0 countries

Sites

N/A

Timeline

Study Start

January 2003

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

October 2003

Actual (reported)

Study Completion

October 2003

Actual (reported)

Brief Summary

Ghrelin administration increases appetite and, in rodents, induces weight gain. The aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 8 participants
Study completion date: October 2003
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2003
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
October 2003
Actual (reported)
Study Completion
October 2003
Actual (reported)
First Submitted
August 6, 2007
Actual (reported)
First Posted
August 7, 2007
Actual (reported)

Last Updated: September 9, 2009
Status Verified: September 2009
Last Update Submitted: September 8, 2009

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (1)

Insulin sensitivity
End of clamp period

Secondary Outcomes (1)

Effects on lipolysis
End of basal and end og clamp period

Study Arms (1)

2

PLACEBO COMPARATOR

Drug: Ghrelin and saline (as placebo)

Interventions

Ghrelin and saline (as placebo)Drug

Intravenous infusion

2

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 50 Years

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

healthy men, age \>= 18 yr age \< 50 yr, body mass index \< 27.5 kg/m2above or equal to 18 yr

You may not qualify if:

Sponsors & Collaborators

University of Aarhus
Otherlead

MeSH Terms

Interventions

GhrelinSodium Chloride

Intervention Hierarchy (Ancestors)

Peptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and ProteinsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

Ole Schmitz, MD
Department of Pharmacology, University of Aarhus, Denmark
STUDY DIRECTOR

Enrollment

8 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: PARTICIPANT
Purpose: HEALTH SERVICES RESEARCH
Intervention Model: CROSSOVER
Sponsor Type: OTHER

Study Record Dates

First Submitted

August 6, 2007

First Posted

August 7, 2007

Study Start

January 2003

Date type not reported

This date has not been verified as actual or estimated.

NCT02944487

A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects

Phase 1Completed

NCT00277199

Comparability DE vs CD-CHO1

Phase 1Completed

NCT01356212

Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device

Phase 1Completed

NCT00543647

Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People

Phase 1Completed

NCT01258491

Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects

Phase 1Completed

NCT01367496

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Phase 1Completed

any disease, use of prescribed medication, age \< 18 yr or \>= 50 yr

Contact the study team to confirm eligibility.

Primary Completion

October 2003

Actual (reported)

Study Completion

October 2003

Actual (reported)

Last Updated

September 9, 2009

Record last verified: 2009-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00512525
Data provider: ClinicalTrials.gov
Source updated: 2009-09-09
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:17:27 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

2

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record